Bayesian Capital Management’s TherapeuticsMD TXMD Stock Holding History

Bayesian Capital Management’s Portfolio TXMD Stock Details TXMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-1,270	Closed	-$24K	–	1086
2022 Q1	$24K	Buy	+1,270	New	+$20K	﹤0.01%	746
2020 Q2	–	Sell	-614	Closed	-$33K	–	795
2020 Q1	$33K	Buy	614 +318	+107%	+$31.5K	0.01%	739
2019 Q4	$36K	Buy	+296	New	+$42.6K	0.01%	577
2018 Q1	–	Sell	-1,086	Closed	-$328K	–	825
2017 Q4	$328K	Buy	+1,086	New	+$302K	0.07%	400

Other funds holding TXMD

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Ergoteles New York $68.2M AUM 36.16% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Gabelli Funds Rye, New York $14.8B AUM 32.24% 1-Year Est. Return

Bayesian Capital Management's TXMD Position: Q2 2022 in Review

Bayesian Capital Management sold out of TherapeuticsMD (TXMD) in Q2 2022, closing a stake of 1,270 shares — an estimated $24K sold.

Bayesian Capital Management first reported a position in TXMD in Q4 2017 and held it in 4 quarters. The position peaked at $328K in Q4 2017. 53 funds tracked by Wall St. Rank hold TXMD as of Q2 2022.

Bayesian Capital Management reported no remaining TherapeuticsMD position as of Q2 2022 after selling out during the quarter.
Bayesian Capital Management sold 1,270 TherapeuticsMD shares in Q2 2022, an estimated $24K.
Bayesian Capital Management first reported a position in TherapeuticsMD in Q4 2017 and held it in 4 quarters.
Bayesian Capital Management's TherapeuticsMD position peaked at $328K in Q4 2017.
53 funds tracked by Wall St. Rank held TherapeuticsMD as of Q2 2022.

Based on Bayesian Capital Management's 13F filing for Q2 2022, filed 15 Aug 2022.